Clinical trial
Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone for Patients With Advanced Non-small Cell Lung Cancer and EGFR Mutations: Phase 3 Randomized Clinical Trial
NCT05445791 is registered in ClinicalTrials.gov with Instituto Nacional de Cancerologia de Mexico as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone for Patients With Advanced Non-small Cell Lung Cancer and EGFR Mutations: Phase 3 Randomized Clinical Trial
- Lead sponsor
- Instituto Nacional de Cancerologia de Mexico
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- July 15, 2021
- Completion date
- July 14, 2027
- Enrollment
- 312 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non small cell lung cancer